CA3098628A1 - Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors - Google Patents
Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors Download PDFInfo
- Publication number
- CA3098628A1 CA3098628A1 CA3098628A CA3098628A CA3098628A1 CA 3098628 A1 CA3098628 A1 CA 3098628A1 CA 3098628 A CA3098628 A CA 3098628A CA 3098628 A CA3098628 A CA 3098628A CA 3098628 A1 CA3098628 A1 CA 3098628A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- oxygen
- nitrogen
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673019P | 2018-05-17 | 2018-05-17 | |
| US62/673,019 | 2018-05-17 | ||
| US201862687599P | 2018-06-20 | 2018-06-20 | |
| US62/687,599 | 2018-06-20 | ||
| US201862697635P | 2018-07-13 | 2018-07-13 | |
| US62/697,635 | 2018-07-13 | ||
| US201862727164P | 2018-09-05 | 2018-09-05 | |
| US62/727,164 | 2018-09-05 | ||
| PCT/US2019/032619 WO2019222468A1 (en) | 2018-05-17 | 2019-05-16 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3098628A1 true CA3098628A1 (en) | 2019-11-21 |
Family
ID=66691041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3098628A Pending CA3098628A1 (en) | 2018-05-17 | 2019-05-16 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12049466B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793997B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7449242B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210010887A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112513036B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019271279A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020021921A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3098628A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2988920T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278291B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020012180A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202011299PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019222468A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| EP4488279A1 (en) | 2023-07-03 | 2025-01-08 | Centro Atlantico del Medicamento S.A (Ceamed, S.A) | Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp) |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030191279A1 (en) | 1999-08-27 | 2003-10-09 | Goldstein Steven Wayne | Urea derivatives useful as anticancer agents |
| US6576632B1 (en) | 1999-08-27 | 2003-06-10 | Pfizer Inc | Biaryl compounds useful as anticancer agents |
| AU781880B2 (en) | 1999-09-17 | 2005-06-16 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| CA2387892A1 (en) | 1999-10-18 | 2001-04-26 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| PT1345900E (pt) | 2000-12-06 | 2007-03-30 | Sanofi Aventis Deutschland | Derivados amidina e guanidina como inibidores do factor xa |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| JP2005507875A (ja) | 2001-08-31 | 2005-03-24 | ユニバーシティ オブ コネチカット | カンナビノイド受容体に作用する新規なピラゾール類似体 |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| AU2003264018A1 (en) | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| CN1691944A (zh) | 2002-08-09 | 2005-11-02 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体-5调节剂的噁二唑 |
| JP4736043B2 (ja) | 2003-03-14 | 2011-07-27 | 小野薬品工業株式会社 | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| KR101104100B1 (ko) | 2003-11-19 | 2012-01-12 | 제이엔씨 석유 화학 주식회사 | 광 중합성 액정 조성물, 그의 중합체 또는 중합체 조성물및 광학보상 소자 |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2005214375A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Triazole compounds and their use as metabotropic glutamate receptor antagonists |
| KR100844593B1 (ko) | 2004-03-09 | 2008-07-07 | 내셔날 헬스 리서치 인스티튜트 | 피롤리딘 화합물 |
| WO2005112540A2 (en) | 2004-05-21 | 2005-12-01 | Merck Patent Gmbh | Liquid crystal compounds, liquid crystal medium and liquid crystal display |
| EP1758579A1 (en) | 2004-05-29 | 2007-03-07 | 7TM Pharma A/S | Crth2 receptor ligands for medicinal uses |
| US20090105218A1 (en) | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
| WO2006015279A1 (en) | 2004-07-28 | 2006-02-09 | Neurogen Corporation | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders |
| NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
| JP4846724B2 (ja) | 2004-09-06 | 2011-12-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重合性液晶材料 |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| DE102004054666A1 (de) | 2004-11-12 | 2006-05-18 | Bayer Cropscience Gmbh | Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| US7678913B2 (en) | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| JP5123668B2 (ja) | 2005-01-10 | 2013-01-23 | エグゼリクシス, インコーポレイテッド | 医薬品としての複素環カルボキサミド化合物 |
| US8084451B2 (en) | 2005-01-10 | 2011-12-27 | University Of Connecticut | Heteropyrrole analogs acting on cannabinoid receptors |
| GB2424881B (en) | 2005-04-07 | 2010-11-24 | Merck Patent Gmbh | Halophenyl derivatives of bisalkylfluorene |
| EP1879881A2 (en) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type i |
| DE602006003432D1 (de) | 2005-05-13 | 2008-12-11 | Lilly Co Eli | Latoren des androgenrezeptors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007024744A2 (en) | 2005-08-21 | 2007-03-01 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptor ligands |
| WO2007061923A2 (en) | 2005-11-18 | 2007-05-31 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008035209A2 (en) | 2006-05-30 | 2008-03-27 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
| JP2009539881A (ja) | 2006-06-09 | 2009-11-19 | アイコス コーポレイション | Dp−2アンタゴニストとしての置換フェニル酢酸 |
| TW200815437A (en) | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| TW200815438A (en) | 2006-06-13 | 2008-04-01 | Bayer Schering Pharma Ag | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| KR101436179B1 (ko) | 2006-09-02 | 2014-09-01 | 메르크 파텐트 게엠베하 | 반응성 메소젠의 배향을 위한 입자 빔 방법 |
| PT2101760E (pt) | 2006-12-08 | 2013-05-07 | Millennium Pharm Inc | Formulações de dose unitária e métodos de tratamento da trombose com um inibidor oral do fator xa |
| US20090062273A1 (en) | 2006-12-15 | 2009-03-05 | Ingo Hartung | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2155687A1 (en) | 2007-05-22 | 2010-02-24 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| KR101077417B1 (ko) | 2007-06-12 | 2011-10-26 | 주식회사 엘지화학 | 위상차 필름, 이를 포함하는 편광판 및 액정 표시 장치 |
| EP2017264A1 (de) | 2007-07-16 | 2009-01-21 | Bayer Cropscience Ag | Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP5057056B2 (ja) | 2007-08-03 | 2012-10-24 | Jsr株式会社 | 液晶配向剤、液晶配向膜の製造方法、ポリアミック酸およびポリイミドならびにジアミン化合物 |
| US8652752B2 (en) | 2007-10-10 | 2014-02-18 | Basf Se | Sulphonium salt initiators |
| JP2009108152A (ja) | 2007-10-29 | 2009-05-21 | Sumitomo Chemical Co Ltd | 重合性化合物および光学フィルム |
| WO2009078992A1 (en) | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| JP2009149754A (ja) | 2007-12-20 | 2009-07-09 | Sumitomo Chemical Co Ltd | 重合性化合物および該重合性化合物を重合してなる光学フィルム |
| US20090270418A1 (en) | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
| JP5219583B2 (ja) | 2008-03-31 | 2013-06-26 | 住友化学株式会社 | 組成物、光学フィルムとその製造方法、光学部材及び表示装置 |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| JP5443720B2 (ja) | 2008-09-05 | 2014-03-19 | 住友化学株式会社 | 組成物、光学フィルム及びその製造方法、光学部材ならびに表示装置 |
| JP2010066630A (ja) | 2008-09-12 | 2010-03-25 | Sumitomo Chemical Co Ltd | 光学フィルムの製造方法及び光学フィルム |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| CN102264737A (zh) | 2008-12-23 | 2011-11-30 | 雅培制药有限公司 | 抗病毒化合物 |
| JP5899607B2 (ja) | 2009-03-16 | 2016-04-06 | 住友化学株式会社 | 化合物、光学フィルム及び光学フィルムの製造方法 |
| KR101641385B1 (ko) | 2009-03-16 | 2016-07-20 | 스미또모 가가꾸 가부시끼가이샤 | 화합물, 광학 필름 및 광학 필름의 제조 방법 |
| JP2011006360A (ja) | 2009-06-26 | 2011-01-13 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
| JP2011042606A (ja) | 2009-08-20 | 2011-03-03 | Sumitomo Chemical Co Ltd | 化合物、光学フィルム及び光学フィルムの製造方法 |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| EP2470183B1 (en) | 2009-08-26 | 2015-09-16 | Merck Sharp & Dohme Corp. | Heterocyclic amide compounds as protein kinase inhibitors |
| EP2475254A4 (en) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| WO2011053825A2 (en) | 2009-10-30 | 2011-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment or prevention of mitochondrial diseases |
| TWI510241B (zh) | 2010-02-18 | 2015-12-01 | Vtv Therapeutice Llc | 苯基-雜芳基衍生物及其使用方法 |
| SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
| EP2569302A1 (en) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
| GB201010359D0 (en) | 2010-06-21 | 2010-08-04 | Univ Nottingham | Compounds for treating proliferative disorders |
| HUE052110T2 (hu) | 2010-07-29 | 2021-04-28 | Rigel Pharmaceuticals Inc | AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk |
| PL3366688T3 (pl) | 2010-12-08 | 2022-05-23 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Podstawione pirazolopirymidyny jako aktywatory glukocerebrozydazy |
| JP5728921B2 (ja) | 2010-12-10 | 2015-06-03 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| WO2012083048A2 (en) | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012083059A1 (en) | 2010-12-15 | 2012-06-21 | Abbott Laboratories | Anti-viral compounds |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| BR112013026341A2 (pt) | 2011-04-13 | 2019-09-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia |
| SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| JP6007417B2 (ja) | 2011-05-31 | 2016-10-12 | レセプトス エルエルシー | 新規glp−1受容体安定剤および調節剤 |
| EP2739144A4 (en) | 2011-06-20 | 2015-04-01 | Alzheimer S Inst Of America Inc | COMPOUNDS AND ITS THERAPEUTIC USE |
| AU2012272815B2 (en) | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| MX342326B (es) | 2011-09-27 | 2016-09-26 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| EP2763532B1 (en) | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| WO2013086229A1 (en) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| WO2013106678A1 (en) | 2012-01-12 | 2013-07-18 | Envivo Pharmaceuticals, Inc. | Tetrasubstituted benzenes |
| TW201348231A (zh) | 2012-02-29 | 2013-12-01 | Amgen Inc | 雜雙環化合物 |
| JP5798066B2 (ja) | 2012-03-08 | 2015-10-21 | 富士フイルム株式会社 | 化合物、液晶組成物、高分子材料およびフィルム |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| EP2671885A1 (en) | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| WO2014000846A1 (en) | 2012-06-26 | 2014-01-03 | dedeMERCK PATENT GMBH | Method of preparing a birefringent polymer film |
| CN110317811A (zh) | 2012-09-17 | 2019-10-11 | 霍夫曼-拉罗奇有限公司 | Usp30抑制剂及其使用方法 |
| US20150291554A1 (en) | 2012-11-02 | 2015-10-15 | Pfizer Inc. | Bruton's Tyrosine Kinase Inhibitors |
| MX2015005375A (es) | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| CN103012428A (zh) | 2013-01-08 | 2013-04-03 | 中国药科大学 | 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途 |
| JP2016518328A (ja) | 2013-03-12 | 2016-06-23 | キュアジェニックス インコーポレイテッド | 癌治療のための化合物 |
| CN104045552B (zh) | 2013-03-13 | 2019-06-11 | 江苏先声药业有限公司 | 作为神经保护剂的药用化合物 |
| CA2905841A1 (en) | 2013-03-14 | 2014-10-02 | Curegenix, Inc. | Quinazoline and naphthyridine derivatives useful in the treatment of fibrotic disorders |
| US9393244B2 (en) | 2013-03-15 | 2016-07-19 | Georgetown University | Increasing parkin activity by administering a deubiquitinating enzyme inhibitor |
| CN105121404A (zh) | 2013-03-15 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物 |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| CA2917767C (en) | 2013-07-12 | 2022-05-03 | Helmholtz-Zentrum Fur Infektionsforschung Gmbh | Cystobactamides |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2918534A1 (en) | 2013-07-25 | 2015-01-29 | Fondazione Telethon | Inhibitors of fapp2 and uses thereof |
| KR101715090B1 (ko) | 2013-08-28 | 2017-03-13 | 한국화학연구원 | 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물 |
| US20150087673A1 (en) | 2013-09-26 | 2015-03-26 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| RU2677884C2 (ru) | 2013-09-30 | 2019-01-22 | Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. | Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| WO2015058832A1 (en) | 2013-10-21 | 2015-04-30 | Merck Patent Gmbh | Method of preparing a birefringent polymer film |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| US9745324B2 (en) | 2013-12-18 | 2017-08-29 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use |
| WO2015106292A1 (en) | 2014-01-13 | 2015-07-16 | Coferon, Inc. | Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same |
| WO2015130790A2 (en) | 2014-02-25 | 2015-09-03 | Board Of Regents, University Of Texas System | Salts of heterocyclic modulators of hif activity for treatment of disease |
| MX376163B (es) | 2014-05-13 | 2025-03-07 | Hoffmann La Roche | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
| EP3147283B1 (en) | 2014-05-22 | 2022-08-17 | North China Pharmaceutical Company., Ltd. | Hydrazine compound as blood coagulation factor xa inhibitor |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| GB201410653D0 (en) | 2014-06-14 | 2014-07-30 | Mission Therapeutics Ltd | Methodologies for measuring isopeptidase activity in biological samples in a high throughput manner |
| CN106065009B (zh) | 2014-06-28 | 2019-03-01 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的化合物及其在药物中的应用 |
| CN106715418A (zh) | 2014-07-07 | 2017-05-24 | 基因泰克公司 | 治疗化合物及其使用方法 |
| WO2016008011A1 (en) | 2014-07-16 | 2016-01-21 | Novogen ltd | Functionalised and substituted indoles as anti-cancer agents |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US9290457B2 (en) | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| US10615343B2 (en) | 2014-09-05 | 2020-04-07 | Merck Patent Gmbh | Formulations and electronic devices |
| WO2016040449A1 (en) | 2014-09-10 | 2016-03-17 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| US9997717B2 (en) | 2014-12-12 | 2018-06-12 | Idemitsu Kosan Co., Ltd. | Organic electroluminescence device and electronic device |
| CN104557862B (zh) | 2014-12-15 | 2017-05-17 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物 |
| CA2978823C (en) | 2014-12-29 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
| LT3277677T (lt) | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| WO2017002120A1 (en) | 2015-07-02 | 2017-01-05 | Yeda Research And Development Co. Ltd. | Selective inhibitors of senescent cells and uses thereof |
| WO2017010399A1 (ja) | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | RORγt阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| WO2017019822A1 (en) | 2015-07-29 | 2017-02-02 | Medivation Technologies, Inc. | Pellet composition containing repair cells |
| WO2017019817A1 (en) | 2015-07-29 | 2017-02-02 | Medivation Technologies, Inc. | Methods and compositions for targeted therapeutics |
| WO2017019830A1 (en) | 2015-07-29 | 2017-02-02 | Medivation Technologies, Inc. | Methods and compositions for targeted therapeutics |
| WO2017040982A1 (en) | 2015-09-02 | 2017-03-09 | The Regents Of The University Of California | Her3 ligands and uses thereof |
| WO2017040194A1 (en) | 2015-09-04 | 2017-03-09 | Dow Agrosciences Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| AU2016366310C1 (en) | 2015-12-09 | 2021-09-09 | Research Triangle Institute | Improved apelin receptor (APJ) agonists and uses thereof |
| JO3793B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |
| GB201522267D0 (en) * | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| CN106986859B (zh) | 2016-01-20 | 2020-02-11 | 广东东阳光药业有限公司 | 吲哚衍生物及其用途 |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN107226805A (zh) | 2016-03-24 | 2017-10-03 | 北京天诚医药科技有限公司 | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 |
| MA43753A (fr) | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| BR112018077075A2 (pt) | 2016-06-29 | 2019-04-30 | Universite De Montreal | heterociclos de biarilmetila |
| CN107619388A (zh) | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | 作为fgfr抑制剂的杂环化合物 |
| CN107619384B (zh) | 2016-07-13 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并杂环衍生物、其制备方法及其在医药上的应用 |
| WO2018024188A1 (zh) | 2016-08-02 | 2018-02-08 | 上海迪诺医药科技有限公司 | 多环化合物、其制备方法、药物组合物及应用 |
| CA3035105C (en) | 2016-08-30 | 2023-09-12 | Dow Global Technologies Llc | Method of attenuating concentration of acrolein |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| CN110291090A (zh) | 2017-01-20 | 2019-09-27 | 利奥制药有限公司 | 作为新型jak激酶抑制剂的双环胺 |
| EP3580190B1 (en) | 2017-02-08 | 2021-08-04 | Helmholtz-Zentrum Dresden - Rossendorf e.V. | In vivo stable hg-197(m) compounds, method for the production thereof and use thereof in nuclear medical diagnostics and endoradionuclide therapy (theranostics) |
| US10744213B2 (en) | 2017-02-14 | 2020-08-18 | Colossus Biopharma Consultants Company, Limited | Fluorescent compounds for imaging of blood vessels and blood flow, and an in vivo screen for pro- and anti-angiogenic agents |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018157857A1 (zh) | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Dub阻害剤としての活性をもつ置換シアノピロリジン類 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| CA3150492A1 (en) | 2019-09-11 | 2021-03-18 | Donna L. Romero | Usp30 inhibitors and uses thereof |
-
2019
- 2019-05-16 IL IL278291A patent/IL278291B2/en unknown
- 2019-05-16 BR BR112020021921-5A patent/BR112020021921A2/pt not_active IP Right Cessation
- 2019-05-16 ES ES19728257T patent/ES2988920T3/es active Active
- 2019-05-16 MX MX2020012180A patent/MX2020012180A/es unknown
- 2019-05-16 US US17/055,161 patent/US12049466B2/en active Active
- 2019-05-16 JP JP2020564429A patent/JP7449242B2/ja active Active
- 2019-05-16 SG SG11202011299PA patent/SG11202011299PA/en unknown
- 2019-05-16 KR KR1020207035718A patent/KR20210010887A/ko not_active Ceased
- 2019-05-16 EP EP19728257.7A patent/EP3793997B1/en active Active
- 2019-05-16 CN CN201980047647.0A patent/CN112513036B/zh active Active
- 2019-05-16 AU AU2019271279A patent/AU2019271279A1/en not_active Abandoned
- 2019-05-16 WO PCT/US2019/032619 patent/WO2019222468A1/en not_active Ceased
- 2019-05-16 CA CA3098628A patent/CA3098628A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210010887A (ko) | 2021-01-28 |
| US12049466B2 (en) | 2024-07-30 |
| ES2988920T3 (es) | 2024-11-22 |
| CN112513036A (zh) | 2021-03-16 |
| IL278291A (cg-RX-API-DMAC7.html) | 2020-12-31 |
| BR112020021921A2 (pt) | 2021-01-26 |
| JP7449242B2 (ja) | 2024-03-13 |
| EP3793997A1 (en) | 2021-03-24 |
| IL278291B2 (en) | 2023-10-01 |
| SG11202011299PA (en) | 2020-12-30 |
| EP3793997B1 (en) | 2024-03-13 |
| US20210198263A1 (en) | 2021-07-01 |
| MX2020012180A (es) | 2021-01-29 |
| WO2019222468A1 (en) | 2019-11-21 |
| AU2019271279A1 (en) | 2020-11-26 |
| IL278291B1 (en) | 2023-06-01 |
| CN112513036B (zh) | 2024-05-24 |
| JP2021524440A (ja) | 2021-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3793997B1 (en) | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | |
| JP7268116B2 (ja) | Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| KR102716960B1 (ko) | 디아자스피로 rock 억제제 | |
| ES2951212T3 (es) | Fenilacetamidas como inhibidores de ROCK | |
| AU2019356011B2 (en) | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors | |
| CN109996792B (zh) | 在治疗cns疾病和疼痛中具有作为毒蕈碱性m1和/或m4受体调节剂活性的杂环化合物 | |
| ES2894128T3 (es) | Inhibidores aminoheterocíclicos de cinco miembros y aminoheterocíclicos bicíclicos de 5,6 o 6,6 miembros de ROCK para el tratamiento de la insuficiencia cardíaca | |
| JP2024525580A (ja) | Irak4タンパク質の分解をターゲティングするための化合物 | |
| BR112020003725A2 (pt) | inibição da peptidase 30 específica de ubiquitina | |
| EP3652168A1 (en) | 5-membered and bicyclic heterocyclic amides as inhibitors of rock | |
| BR112021003496A2 (pt) | composto, composição farmacêutica, e, métodos para tratar doença cardíaca, para tratar uma doença ou afecção associada à cardiomiopatia hipertrófica, ou afecção que está associada ao espessamento secundário da parede do ventrículo esquerdo, ou afecção que está associada à pequena cavidade do ventículo esquerdo e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia miocárdica ou fibrose cardíaca, ou afecção selecionada dentre distrofias musculares e doenças de armazenamento de glicogênio, para inibir o sarcômero cardíaco | |
| JP2014526560A (ja) | β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法 | |
| CA3185634A1 (en) | Tricyclic heterocycles | |
| CA3201540A1 (en) | Aromatic heterocyclic compound, pharmaceutical composition and use thereof | |
| CN108341819B (zh) | 磷酸二酯酶抑制剂及其用途 | |
| TW202440091A (zh) | Nampt調節劑 | |
| CA3223611A1 (en) | Ferroptosis modulators, preparations, and uses thereof | |
| CA3236550A1 (en) | Spirotricycle ripk1 inhibitors and methods of uses thereof | |
| JP7733578B2 (ja) | Usp19の抑制 | |
| EA042925B1 (ru) | Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30 | |
| TW202402751A (zh) | 鐵死亡調節物、製劑及其使用 | |
| HK40036033B (en) | Inhibiting ubiquitin specific peptidase 30 | |
| HK40036033A (en) | Inhibiting ubiquitin specific peptidase 30 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20240827 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251106 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260630 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |